Physician profile
Michael Fishbaugh
NPI 1225036197
$4,344.14
in general payments reported to CMS, 2019-2025
22 companies · $190 in 2025
The $190 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,540 · 2020: $352 · 2021: $633 · 2022: $655 · 2023: $493 · 2024: $481 · 2025: $190.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,146 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,146.17 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,601.82 | 2019-2025 | Total30, Precision7, Precision 1 |
| Coopervision INC. | $407.98 | 2019-2023 | Myday Contact Lens |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $317.12 | 2019-2021 | |
| Johnson & Johnson Vision Care, INC. | $294.53 | 2022-2024 | |
| Sun Pharmaceutical Industries INC. | $241.94 | 2019-2024 | Cequa |
| Bausch & Lomb Americas INC. | $161.24 | 2022-2025 | Xiidra, Miebo, Vyzulta |
| Biotissue Holdings INC. | $161.23 | 2020-2023 | |
| Aerie Pharmaceuticals, INC. | $131.43 | 2019-2021 | |
| Notal Vision, INC. | $130.90 | 2021 | |
| Oyster Point Pharma, INC. | $130.55 | 2022-2024 | Tyrvaya |
| Allergan, INC. | $129.60 | 2019-2021 | |
| Shire North American Group INC | $111.24 | 2019 | |
| Novartis Pharmaceuticals Corporation | $102.10 | 2019-2023 | |
| Abbvie INC. | $79.43 | 2023-2025 | |
| Dompe US, INC. | $73.75 | 2022-2024 | Oxervate |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optos, INC. | $68.31 | 2020-2021 | |
| Lkc Technologies, INC. | $57.66 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $34.37 | 2025 | Xdemvy |
| Quidel Corporation | $34.02 | 2021 | |
| Maculogix, INC. | $31.84 | 2019-2021 | |
| Harrow Eye, LLC | $31.22 | 2024-2025 | Vevye |
| Kala Pharmaceuticals, INC. | $11.86 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Fishbaugh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.